Quick Answer
Viking Therapeutics, Inc. reported Net Income Loss of -$359.64 million for the year ending 2025.
- Viking Therapeutics, Inc. showed a decrease of -227.1% in Net Income Loss from 2024 to 2025.
- This data is from Viking Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on February 11, 2026.
- XBRL data for this metric is available from 2014 to 2025 (12 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 12 years of available data (2014 to 2025), Viking Therapeutics, Inc.'s Net Income Loss has declined by 1,543.4%.
- Historical annual values: Fiscal year 2025: -$359.64 million | Fiscal year 2024: -$109.96 million | Fiscal year 2023: -$85.90 million | Fiscal year 2022: -$68.87 million | Fiscal year 2021: -$54.99 million | Fiscal year 2020: -$39.50 million | Fiscal year 2019: -$25.78 million | Fiscal year 2018: -$22.06 million | Fiscal year 2017: -$20.58 million | Fiscal year 2016: -$14.73 million | Fiscal year 2015: -$23.40 million | Fiscal year 2014: -$21.88 million.
- Data sourced from SEC EDGAR public filings as of June 20, 2026.
Last verified: